Announced details
Initial and maintenance therapy for early Alzheimer's disease (AD), with at-home administration
Regarding the ease of use of the autoinjector, 94% of people living with early AD and care partners reported that it was easy to use. Initial therapy consists of 2 injections of 250 mg, for a total of 500 mg, administered once weekly, with each administration completed in approximately 15 seconds. Maintenance therapy consists of 360 mg administered once weekly.
Eisai and Biogen have jointly developed and marketed Alzheimer's disease treatments since 2014 and jointly commercialize and co-promote lecanemab. Eisai leads development and regulatory submissions globally and holds final decision-making authority. The FDA is the approving authority.
Biogen Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, founded in 1978. Its CEO is Christopher A. Viehbacher. The U.S. Food and Drug Administration (FDA) is the U.S. regulatory authority.
The impact on the forecast for the fiscal year ending March 2027 is expected to be immaterial, and there is no change to the earnings forecast announced on 15 May 2026.
The company does not address Contract Value / Offering price.
The Clarity AD trial, a long-term extension (LTE) substudy of the trial, and an autoinjector acceptability study involving in-person interviews with 50 people living with early AD and 50 care partners
| Item | Details |
|---|---|
| Names of Products / Services Covered | Leqembi, LEQEMBI IQLIK |
| Counterparty | U.S. Food and Drug Administration (FDA), Biogen Inc. (Nasdaq: BIIB) |
| Counterparty overview | Biogen Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, founded in 1978. Its CEO is Christopher A. Viehbacher. The U.S. Food and Drug Administration (FDA) is the U.S. regulatory authority. |
| Relationship with the Company | Eisai and Biogen have jointly developed and marketed Alzheimer's disease treatments since 2014 and jointly commercialize and co-promote lecanemab. Eisai leads development and regulatory submissions globally and holds final decision-making authority. The FDA is the approving authority. |
| Contract Date | 2014 (start of the collaboration between Eisai and Biogen for the joint development and marketing of Alzheimer's disease treatments) |
| Launch date | Late August 2026 (scheduled; U.S. launch) |
| Applicable area | Initial and maintenance therapy for early Alzheimer's disease (AD), with at-home administration |
| Quantitative Effects | Regarding the ease of use of the autoinjector, 94% of people living with early AD and care partners reported that it was easy to use. Initial therapy consists of 2 injections of 250 mg, for a total of 500 mg, administered once weekly, with each administration completed in approximately 15 seconds. Maintenance therapy consists of 360 mg administered once weekly. |
| Impact on Business Performance | The impact on the forecast for the fiscal year ending March 2027 is expected to be immaterial, and there is no change to the earnings forecast announced on 15 May 2026. |
| Source | The Clarity AD trial, a long-term extension (LTE) substudy of the trial, and an autoinjector acceptability study involving in-person interviews with 50 people living with early AD and 50 care partners |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The FDA approved a supplemental biologics license application. The agency explained that subcutaneous administration could reduce the burden of clinic visits and reliance on healthcare resources associated with intravenous administration, while improving convenience and flexibility.